Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3629698 | 0.81 | MEN1 (0.36) | LMNATSHRCYP3A4PMP22KCNQ2 | |
| SCHEMBL25076093 | 0.81 | CYP4F2 (0.39) | MAPTLMNACYP4F2CYP4A11TSHR | |
| SCHEMBL5257795 | 0.81 | CYP4F2 (0.39) | MAPTLMNACYP4F2CYP4A11TSHR | |
| SCHEMBL2804738 | 0.79 | KCNQ2 (0.34) | KCNQ2 | |
| SCHEMBL26039065 | 0.79 | ALDH1A1 (0.39) | MAPTCYP4F2CYP4A11TSHRCYP1A2 | |
| SCHEMBL1973881 | 0.78 | DGAT1 (0.36) | MAPTKCNQ2 | |
| SCHEMBL21949878 | 0.78 | CYP2C9 (0.38) | MAPTCYP4F2CYP4A11TSHRALDH1A1 | |
| SCHEMBL8305688 | 0.77 | CYP4F2 (0.41) | MAPTLMNACYP4F2CYP4A11TSHR | |
| SCHEMBL12631752 | 0.76 | CYP4F2 (0.40) | MAPTCYP4F2CYP4A11TSHRMEN1 | |
| SCHEMBL2729168 | 0.76 | MAPT (0.36) | MAPTTAAR1LMNACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105748480-A | Methods of treatment of skin ulcers | 宾夕法尼亚大学理事会 | 2016-07-13 | — | — | CN | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-9029383-B2 | Methods of treatment of skin ulcers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2008048867-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | MAPT 3155/4885TAAR1 1042/4885LMNA 1440/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | MAPT 4864/4885TAAR1 4459/4885LMNA 1073/4885 |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | MAPT 3121/4885TAAR1 1083/4885LMNA 1388/4885 |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GPR6, CNR1, NR3C1 | MAPT 4568/4885TAAR1 113/4885LMNA 1787/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | MAPT 199/4885TAAR1 2004/4885LMNA 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.